These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
393 related items for PubMed ID: 18792835
21. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Thöne J, Ellrichmann G, Seubert S, Peruga I, Lee DH, Conrad R, Hayardeny L, Comi G, Wiese S, Linker RA, Gold R. Am J Pathol; 2012 Jan; 180(1):267-74. PubMed ID: 22152994 [Abstract] [Full Text] [Related]
22. Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Diem R, Sättler MB, Merkler D, Demmer I, Maier K, Stadelmann C, Ehrenreich H, Bähr M. Brain; 2005 Feb; 128(Pt 2):375-85. PubMed ID: 15601662 [Abstract] [Full Text] [Related]
28. The immunology of multiple sclerosis: disease mechanisms and therapeutic targets. Holmøy T. Minerva Med; 2008 Apr; 99(2):119-40. PubMed ID: 18431322 [Abstract] [Full Text] [Related]
29. Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators. Yong VW, Zabad RK, Agrawal S, Goncalves Dasilva A, Metz LM. J Neurol Sci; 2007 Aug 15; 259(1-2):79-84. PubMed ID: 17382965 [Abstract] [Full Text] [Related]
30. [Neuronal injury in multiple sclerosis]. Correale J, Meli F, Ysrraelit C. Medicina (B Aires); 2006 Aug 15; 66(5):472-85. PubMed ID: 17137182 [Abstract] [Full Text] [Related]
31. Early life exposure to lipopolysaccharide suppresses experimental autoimmune encephalomyelitis by promoting tolerogenic dendritic cells and regulatory T cells. Ellestad KK, Tsutsui S, Noorbakhsh F, Warren KG, Yong VW, Pittman QJ, Power C. J Immunol; 2009 Jul 01; 183(1):298-309. PubMed ID: 19542441 [Abstract] [Full Text] [Related]
32. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Sriram S, Steiner I. Ann Neurol; 2005 Dec 01; 58(6):939-45. PubMed ID: 16315280 [Abstract] [Full Text] [Related]
33. Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Kerschensteiner M, Stadelmann C, Dechant G, Wekerle H, Hohlfeld R. Ann Neurol; 2003 Mar 01; 53(3):292-304. PubMed ID: 12601697 [Abstract] [Full Text] [Related]
34. Therapeutic potential of LIF in multiple sclerosis. Slaets H, Hendriks JJ, Stinissen P, Kilpatrick TJ, Hellings N. Trends Mol Med; 2010 Nov 01; 16(11):493-500. PubMed ID: 20870461 [Abstract] [Full Text] [Related]
39. [Axonal damage and its significance for the concept of neurodegeneration in multiple sclerosis]. Recks MS, Bader J, Kaiser CC, Schroeter M, Fink GR, Addicks K, Kuerten S. Fortschr Neurol Psychiatr; 2011 Mar 15; 79(3):161-70. PubMed ID: 21394707 [Abstract] [Full Text] [Related]
40. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond. Aharoni R. Autoimmun Rev; 2013 Mar 15; 12(5):543-53. PubMed ID: 23051633 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]